Acute Lymphoblastic Leukaemia Recurrent Recruiting Phase 2 Trials for Cytarabine (DB00987)

Also known as: Acute, recurrent Lymphoblastic Leukaemia / Acute, recurrent Lymphoblastic Leukemia / Recurrent Acute lymphoblastic leukemia / Acute, relapsed Lymphoblastic Leukemia / Relapsed Acute Lymphoblastic Leukemia / Acute lymphoblastic leukemia recurrent / Relapsed ALL / Acute lymphocytic leukemia recurrent / Acute lymphocytic leukaemia recurrent

IndicationStatusPhase
DBCOND0083559 (Acute Lymphoblastic Leukaemia Recurrent)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03147612Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaTreatment
NCT03263572Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaTreatment
NCT03575325Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic LeukemiaTreatment